Nephrology Products
Select a product to view details
Nesbell® Darbepoetin Alfa
Highlight
- First Darbepoetin alfa similar
- Improved convenience with once-every-1-to-4 week dosing
- Proven equivalent in efficacy and long-term safety compared to the reference drug
Indication
Anemia associated with chronic kidney disease (CKD) in patients on hemodialysis or not on dialysis.
Specification:
- Form: Solution for injection (prefilled syringe)
- Strength: 20 · 30 · 40 μg
- Pack: Box, 1 prefilled syringe
- REG. BPM: DKI2284401143A1 (20 μg)
Nesbell® Darbepoetin Alfa product range:
Nesbell® Darbepoetin Alfa 20 µg
Nesbell® Darbepoetin Alfa 30 µg
Nesbell® Darbepoetin Alfa 40 µg
.
Renogen® Epoetin Alfa
Highlight
- Complete Strength of EPO Alfa
- Listed in E-Catalogue
- Local Manufactured
Indication
- Anemia caused by renal insufficiency, including patients with hemodialysis and non-hemodialysis due to chronic renal failure.
- Anemia caused by non-myeloid malignancy applied chemotherapy, other than those with anemia caused by other factors in the treatment of cancer patients (e.g. iron or folate deficiency, hemolysis or intestinal tract bleeding)
Specification:
- Form: Solution for injection (prefilled syringe)
- Strength: 2,000 IU · 3,000 IU · 4,000 IU ·5,000 IU
- Pack: Box, 1 prefilled syringe
- REG. BPM: DKL2257901243A1 (2,000 IU) · DKL2257901243B1 (3,000 IU) · DKI2046400243C1 (4,000) · DKI2046400243E1 (5,000 IU)
- E-Catalogue: Listed
Renogen® Epoetin Alfa product range:
Renogen® Epoetin Alfa 2000 IU
Renogen® Epoetin Alfa 3000 IU
Renogen® Epoetin Alfa 4000 IU
Renogen® Epoetin Alfa 5000 IU
.